Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study

Abstract Purpose This study aimed to investigate the real-world use and clinical outcomes of tixagevimab/cilgavimab in China during the Omicron outbreak in late 2022. Methods This observational, real-world study included patients who received tixagevimab/cilgavimab from July 9 to December 30, 2022,...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jianhua You, Haidi Wu, Jiaxin Tian, Jianru Wen, Wenbo Shi, Zhi Wang, Yanjun Du, Hongwei Xu, Hanyu Wei, Xiang Li, Wenyan Kang, Min Zhou, Zhidong Gu, Jieming Qu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-10-01
Edice:	Virology Journal
Témata:	COVID-19 Omicron variant Tixagevimab/cilgavimab Chinese
On-line přístup:	https://doi.org/10.1186/s12985-024-02509-5
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!